Literature DB >> 2308997

Gene transfer by electroporation: a model for gene therapy.

A Keating1, F Toneguzzo.   

Abstract

We examined electroporation for the introduction of DNA into hematopoietic cells in order to develop an in vitro model for human gene therapy. We demonstrated that electroporation is a relatively efficient and reproducible method of gene transfer in permanent hematopoietic lines. Characterization of DNA transfer revealed that genes are integrated in single or low copy number. We showed that human normal granulopoietic progenitors can express the transferred gene at a frequency of more than two percent. Although the progeny of erythroid progenitors failed to express transferred genes, the frequency of transfer to erythroid clones, as detected by the polymerase chain reaction, was moderately high (16%). In order to improve efficiency of expression, we examined the effect of different viral and cellular promoters in the hematopoietic lines K562 and KG1a as well as in marrow stromal cells. We found that Rous Sarcoma virus LTR was the most active promoter in K562 while the murine cytomegalovirus immediate early promoter was highly active in KG1a and marrow stromal cells. Further improvements in the efficiency of DNA transfer and expression with electroporation are likely to result in a successful hematopoietic model for gene therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308997

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  10 in total

1.  Electroporation of viral transactivator proteins into lymphocyte suspension cells.

Authors:  F Kashanchi; J F Duvall; J N Brady
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

2.  Transient transfection of oligodendrocyte progenitors by electroporation.

Authors:  W H Krueger; D L Madison; S E Pfeiffer
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 3.  Human cancer and gene therapy.

Authors:  G Schmidt-Wolf; I G Schmidt-Wolf
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

Review 4.  A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium.

Authors:  Adarsha Koirala; Shannon M Conley; Muna I Naash
Journal:  Biomaterials       Date:  2013-06-22       Impact factor: 12.479

5.  Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.

Authors:  Philip M Zakas; H Trent Spencer; Christopher B Doering
Journal:  J Genet Syndr Gene Ther       Date:  2011-11-16

6.  Electroporation markedly improves Sleeping Beauty transposon-induced tumorigenesis in mice.

Authors:  S Jung; H-J Choi; H-K Park; W Jo; S Jang; J-E Ryu; W-J Kim; E-S Yu; W-C Son
Journal:  Cancer Gene Ther       Date:  2014-07-04       Impact factor: 5.987

7.  Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy.

Authors:  R Bergan; Y Connell; B Fahmy; L Neckers
Journal:  Nucleic Acids Res       Date:  1993-07-25       Impact factor: 16.971

Review 8.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 9.  Gene therapy in surgical oncology.

Authors:  S P Gagandeep; G J Poston; A R Kinsella
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

10.  Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

Authors:  Marnie L Elizaga; Shuying S Li; Nidhi K Kochar; Gregory J Wilson; Mary A Allen; Hong Van N Tieu; Ian Frank; Magdalena E Sobieszczyk; Kristen W Cohen; Brittany Sanchez; Theresa E Latham; David K Clarke; Michael A Egan; John H Eldridge; Drew Hannaman; Rong Xu; Ayuko Ota-Setlik; M Juliana McElrath; Christine Mhorag Hay
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.